Cannabinoid Receptor 2, Human Control Peptide, NT (CB2)

Control Peptide for C1075-76 (affinity purified antibody) and C1075-75D (antiserum).\n\nCannabinoids is a group of C21 compounds present in Cannabis sativa L.. They are carboxylic acids, analogs and transformation products. They are the active ingredients found in hasish and marihuana. (-)-trans-D9-tetrahydrocannabinol (D9-THC) is the major psychopharmacologically active component of Cannabis. Cannabis affects cognition and memory, euphoria and sedation, and antinociception (analgesia) without the respiratory depression problems associated with opioid analgesics. D9-THC is also immunosuppressive and impairs cell-mediated immunity, humoral immunity and cellular defenses against a variety of infectious agents both in vivo and in vitro. To date, two sub-types of the G-protein coupled cannabinoid receptor, CB1 and CB2, have been identified. The first brain-derived endogenous cannabinoids, an unsaturated fatty-acid ethanolamide, arachidonylethanolamide (AEA, also called anandamide) was found in brain. AEA has higher affinity for the CB1 than for the CB2. CB2 (rat 410aa, mouse 347aa, human 360aa; ~45% homology with CB1) also inhibit adenylate cyclase activity via a pertussis toxin-sensitive G-protein. Unlike CB1, CB2 does not modulate the activity of either Q-type Ca2+ or inwardly rectifying K+ channels. High level of CB2 expression was found in HL60 cells that had been differentiated into granulocytes or macrophages. It is also expressed in splenic macrophages and monocytes. It is not expressed in splenic T cells, mature blood neutrophils, thymus, liver, brain, lungor kidney. This indicates that the distribution is quite different from that of the CB1 receptor. High levels of CB2 mRNA was found in B-cells and natural killer cells, to a moderate extent in monocytes and only minimally in polymorphonuclear leukocytes, T4- and T8- cells. CNS responses to cannabinoid compounds are believed to be mediated largely by the CB1 receptor.\n\nApplications: \nSuitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot due to its low molecular weight. Other applications not tested.\n\nRecommended Dilution:\nELISA: 50-100ng per well.\nAntibody Blocking: 5-10ug per 1ug of C1075-76 (affinity purified antibody) or 1ul C1075-75D \n(antiserum).\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage, store at -20 degrees C. Aliquots are stable for at least 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C1075-76A

Size

100ug

Applications

ELISA

Form

Supplied as a lyophilized powder from PBS, 0.05% sodium azide.

Purity

Highly Purified

References

1. Munro, S., et al., Nature 365: 61-65 (1993). 2. Shire, D., et al., Biochim. Biophys. Acta 1307: 132-136 (1996). 3. Griffin, G., et al., J. Pharmacol. Exp. Therap. 292: 886-894 (2000).

Additional Info

Synthetic peptide 14aa sequence near the extracellular, N-terminus of human CB2. No significant sequence homology with CB1 receptors.\nSpecies Sequence Homology: Human: The sequence is unique to human. Rat and mouse: 71%.